Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Reggio Emilia – page 16

246 clinical trials in Reggio Emilia, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Reggio Emilia at a glance
246
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

246 trials in Reggio Emilia

Open in trial search

Hodgkin's disease

Not recruiting

Study of Atezolizumab and Drug Combination for Patients with Relapsed or Refractory Hodgkin's Lymphoma Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione Italiana Linfomi Ets

Myelofibrosis+1

Not recruiting

Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Kartos Therapeutics Inc.

Diffuse large B-cell lymphoma

Not recruiting

Study on Prednisone and Vitamin D for Elderly Patients with Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Colecalciferol
  • Sponsor:Fondazione Italiana Linfomi Ets

Ductal adenocarcinoma of pancreas

Not recruiting

Study of SBP-101, Nab-Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Panbela Therapeutics Inc.

Transitional cell carcinoma

Not recruiting

Study of drug combination with gemcitabine, cisplatin, carboplatin and avelumab in patients with advanced urothelial cancer to evaluate response to platinum-based chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Gastric cancer

Not recruiting

Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Non-small cell lung cancer

Not recruiting

Study on the Effectiveness and Safety of Osimertinib for Patients with EGFR Mutation-Positive Stage II-IIIB Non-Small Cell Lung Cancer After Tumor Removal

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Endometrial cancer

Not recruiting

Study on MK-2870 for Patients with Endometrial Cancer After Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Cardiac failure

Not recruiting

Study of XXB750 and Drug Combination for Patients with Heart Failure

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azilsartan Medoxomil
  • Sponsor:Novartis Pharma AG

Asthma

Not recruiting

Study on the Effects of Dexpramipexole for Adolescents and Adults with Severe Eosinophilic Asthma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Areteia Therapeutics Inc.

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alkylating agents
  • Sponsor:Geron Corp.

Essential thrombocythaemia

Not recruiting

Study on Bomedemstat for Patients with Essential Thrombocythemia Not Responding to or Intolerant of Hydroxyurea, Comparing with a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bomedemstat
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Reggio Emilia

What the registry says about research in the country

01 Oncology - Solid Tumors

Innovative clinical trials focusing on metastatic colorectal cancer, non-small cell lung cancer, and gastric cancer. Research evaluates novel therapeutic approaches including targeted therapies and immunotherapy combinations.

  • Colorectal Cancer Treatments
  • Lung Cancer Therapies
  • Gastrointestinal Oncology

Studies include assessment of treatment efficacy and novel drug combinations for advanced stage cancers.

02 Hematologic Malignancies

Groundbreaking research in B-cell lymphomas and chronic myeloid leukemia. Studies evaluate innovative treatment approaches including targeted therapies and combination protocols.

  • Lymphoma Treatments
  • Leukemia Therapies
  • Novel Drug Combinations

Focus on improving patient outcomes through personalized treatment approaches.

03 Autoimmune Conditions

Clinical trials investigating treatments for Sjögren's Syndrome and other inflammatory conditions. Research aims to evaluate long-term safety and efficacy of novel therapeutic agents.

  • Inflammatory Disorders
  • Autoimmune Diseases
  • Novel Therapeutics

Studies focus on developing safer and more effective treatment options for patients.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.